Multiplexing can streamline tests for food allergies, autoimmune diseases, and more

With the fall conference season already gearing up, we can’t help but reflect on the summer events we attended over these past few months. Most recently, Luminex representatives attended the annual meeting held by the Association of Medical Laboratory Immunologists (AMLI), which never fails to update attendees about news of the latest innovations and issues facing the diagnostic immunology field.

[thumbnail]

Once again, the VALID Act is center stage

AMLI 2022, held in Salt Lake City, brought together a community of healthcare providers, lab directors, clinical scientists, and commercial diagnostic developers for thoughtful dialogue and discussions about new breakthroughs. Once again, as it had been for clinical chemistry experts attending AACC 2022, the VALID (Verifying Accurate Leading-edge IVCT Development) Act proved to be a considerable concern within the diagnostic immunology community. There is apprehension across clinical laboratories about how this bill could affect laboratory-developed tests (LDTs) if voted into law. While tasking the FDA with LDT regulation has always been a hot-button issue among clinical lab professionals, there is great awareness of the pivotal role LDTs played in allowing healthcare teams to care for patients during the COVID-19 pandemic. AMLI attendees reaffirmed the need to ensure that patient care is always prioritized.

Many clinical lab users of Luminex assay platforms prefer the flexibility of creating their own LDTs based on Bio-Rad Laboratories hosted a seminar about HIV diagnostics featuring their xMAP-based multiplexed kit for HIV antigen and antibody detection. Thermo Fisher Scientific also gave a presentation about autoimmunity and data-driven approaches for analysis.

Of course, we would like to thank all the AMLI attendees who took time out of their busy event schedule to connect with us at our booth in the exhibit hall. We were excited to see so many researchers interested in learning more about xMAP multiplexing technology, as well as Luminex’s ability to support and streamline diagnostic and research needs within immunology using exponential speed and unmatched accuracy.